Reduced intensity hematopoietic cell transplant using best available donor and posttransplant cyclophosphamide is safe and curative for transfusion-dependent thalassemia
Year: 2026
Type: article
Abstract: Over 300,000 live births annually are affected by hemoglobinopathies worldwide. Of these, transfusion-dependent thalassemias (TDTs) result in severe phenotypes that significantly impact quality of life, shorten life expectancy, and incur high lifetime healthcare costs driven by recurrent transfusions and chelation therapy. Allogeneic hematopoietic cell transplantation (allo-HCT) is curative but limited by donor availability, regimen toxicity, graft-versus-host disease (GVHD), and transplant-related mortality. We present our single-center experience of TDT patients who underwent allo-HCT using a reduced-intensity conditioning (RIC) regimen (anti-thymocyte globulin, fludarabine, cyclophosphamide, total body irradiation) and posttransplant cyclophosphamide (PTCy)-based GVHD prophylaxis. Twenty-five consecutive children and young adults (ages 2-23 years, median 9) with TDT (beta-thalassemia major n=21, hemoglobin E-beta thalassemia n=3, hemoglobin D-beta thalassemia n=1) underwent HCT from July 2013 to November 2024. Bone marrow was the most common graft source (n=23, 92% of all patients), and haploidentical donors were the most common donor type (n=19, 76% of all patients). Neutrophil and platelet recovery occurred at median 21 days (range 13-38) and 26 days (range 16-88), respectively. Five patients (20%) developed grade I-II acute GVHD; none developed grade III-IV acute GVHD. Two (8%) developed mild chronic GVHD. At a median follow-up of 5.6 years (range 0.7-10), 5-year overall survival was 100%, transfusion-free survival 96%, and thalassemia-free-GVHD-free survival 96% - one patient experienced near-complete loss of donor chimerism with return of the TDT phenotype. Our RIC platform with best-available donor and PTCy-based GVHD prophylaxis significantly reduces post-HCT complications while providing durable transfusion independence, offering a proven, accessible, curative option for TDT.
Source: Haematologica
Authors: Yiouli P. Ktena, Megan Burris, Rebecca Berger, Kathryn Duke, Sara Newton, Kristen Rodenbush, Jessica D. Murphy, Lisa Vindiola, Liam M. Cooke, Hua-Ling Tsai, Challice L. Bonifant, Allen R. Chen, Christopher J. Gamper, Nicolas J. Llosa, Elias T. Zambidis, Katherine Liddle, Richard J. Jones, Javier Bolaños-Meade, Heather J. Symons, Kenneth R. Cooke
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: transfusion-dependent thalassemia, beta-thalassemia major, HbE/β-thalassemia, reduced-intensity conditioning, post-transplant cyclophosphamide, graft-versus-host disease prophylaxis, haploidentical donor, antithymocyte globulin, fludarabine, total body irradiation, transfusion independence, donor chimerism, pediatric and young adult patients
Open Access status: gold
Estimated APC paid: $2,157
OpenAlex ID: W7236580319
